Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression
Year: 2014
Type: article
Abstract: The Hodgkin Reed–Sternberg (HRS) cells of classical Hodgkin lymphoma (cHL) are surrounded by a number of reactive and inflammatory cells. 1 The ability of HRS cells to evade immune surveillance is linked to a network of cytokines and chemokines that are produced by HRS and the surrounding cells, 1 , 2 , 3 in addition to the occasional aberrant expression of programmed death ligand-1 (PDL-1) by HRS 4 that inhibits the activation of PD1-expressing T lymphocytes. Histone deacetylase (HDAC) inhibitors can alter the levels of cytokines and chemokines in vitro , favoring a TH1-type immune response. 5 HDAC inhibitors also enhance antitumor immunity by HDAC11-mediated upregulation of OX40L. 5
Source: Blood Cancer Journal
DOI: 10.1038/bcj.2014.58
Institutions: The University of Texas MD Anderson Cancer Center, Universitat Autònoma de Barcelona, Hospital de Sant Pau, Hadassah Medical Center, University of Bologna, The University of Melbourne, Peter MacCallum Cancer Centre, City Of Hope National Medical Center, City of Hope, Mayo Clinic, Novartis (United States), University of Cologne, University Hospital Cologne
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,290
Funder: National Cancer Institute
Award: Cancer Center Support Grant
OpenAlex ID: W1993916129